NCT06207877View on ClinicalTrials.gov

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

October 16, 2024

Study Completion Date

November 22, 2024

Conditions
Obesity
Interventions
DRUG

Cagrilintide

Cagrilintide will be administered subcutaneously.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06207877 - A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight | Biotech Hunter | Biotech Hunter